Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.49 |
| ▸ | CHKA | P35790 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8486989 | 0.94 | CHIA (0.53) | CHIAHRH4HTR3EHTR3BHTR3A | |
| SCHEMBL681850 | 0.86 | CYP1A2 (0.49) | — | |
| SCHEMBL3292521 | 0.86 | NCF1 (0.61) | CHIAHRH4NCF1HTR3EHTR3B | |
| SCHEMBL3063649 | 0.85 | CYP2C19 (0.51) | — | |
| SCHEMBL25925455 | 0.80 | CHIA (0.58) | CHIAHRH4HTR3EHTR3BHTR3A | |
| SCHEMBL30607656 | 0.79 | NCF1 (0.51) | CHIAHRH4NCF1HTR3EHTR3B | |
| SCHEMBL14818768 | 0.79 | HSD11B1 (0.51) | CHIAHRH4HTR3EHTR3BHTR3A | |
| SCHEMBL3081290 | 0.76 | CYP1A2 (0.52) | — | |
| SCHEMBL17486665 | 0.76 | KDM4E (0.39) | CHIA | |
| SCHEMBL2417746 | 0.76 | EPHX2 (0.55) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-2968299-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-2968299-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2968299-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014150258-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014150258-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHIA 2826/4885CHKA 3885/4885HRH4 3804/4885 |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHIA 2826/4885CHKA 3885/4885HRH4 3804/4885 |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CHIA 2826/4885CHKA 3885/4885HRH4 3804/4885 |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHIA 2826/4885CHKA 3885/4885HRH4 3804/4885 |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CHIA 2826/4885CHKA 3885/4885HRH4 3804/4885 |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CHIA 2826/4885CHKA 3885/4885HRH4 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.